Vivani Medical (NASDAQ:VANI – Get Free Report) is expected to be issuing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($0.07) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. On average, analysts expect Vivani Medical to post ($0.30) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Vivani Medical Stock Performance
Shares of NASDAQ:VANI opened at $1.07 on Thursday. The business’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.25. The stock has a market cap of $96.51 million, a PE ratio of -3.06 and a beta of 2.51. Vivani Medical has a one year low of $0.92 and a one year high of $1.66.
Wall Street Analyst Weigh In
VANI has been the topic of several recent research reports. Wall Street Zen upgraded Vivani Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vivani Medical presently has an average rating of “Hold” and an average target price of $3.75.
View Our Latest Research Report on VANI
About Vivani Medical
Vivani Medical, Inc is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.
The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes.
Read More
- Five stocks we like better than Vivani Medical
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
